nodes	percent_of_prediction	percent_of_DWPC	metapath
Bicalutamide—Coronary artery disease—Varenicline—nicotine dependence	0.0442	0.0498	CcSEcCtD
Bicalutamide—Cyst—Varenicline—nicotine dependence	0.0261	0.0294	CcSEcCtD
Bicalutamide—Intestinal obstruction—Varenicline—nicotine dependence	0.0256	0.0289	CcSEcCtD
Bicalutamide—Nephrolithiasis—Varenicline—nicotine dependence	0.0217	0.0245	CcSEcCtD
Bicalutamide—Tenderness—Varenicline—nicotine dependence	0.02	0.0225	CcSEcCtD
Bicalutamide—Nocturia—Varenicline—nicotine dependence	0.0188	0.0212	CcSEcCtD
Bicalutamide—Influenza like illness—Varenicline—nicotine dependence	0.017	0.0191	CcSEcCtD
Bicalutamide—Hypertonia—Varenicline—nicotine dependence	0.0153	0.0172	CcSEcCtD
Bicalutamide—Diabetes mellitus—Varenicline—nicotine dependence	0.0146	0.0164	CcSEcCtD
Bicalutamide—Libido decreased—Varenicline—nicotine dependence	0.0137	0.0154	CcSEcCtD
Bicalutamide—Hot flush—Varenicline—nicotine dependence	0.0136	0.0153	CcSEcCtD
Bicalutamide—Menopausal symptoms—Varenicline—nicotine dependence	0.0134	0.0151	CcSEcCtD
Bicalutamide—Atrial fibrillation—Varenicline—nicotine dependence	0.0134	0.0151	CcSEcCtD
Bicalutamide—Arthritis—Varenicline—nicotine dependence	0.0131	0.0147	CcSEcCtD
Bicalutamide—Hypoglycaemia—Varenicline—nicotine dependence	0.013	0.0146	CcSEcCtD
Bicalutamide—Cerebrovascular accident—Varenicline—nicotine dependence	0.0129	0.0146	CcSEcCtD
Bicalutamide—Disturbance in sexual arousal—Varenicline—nicotine dependence	0.0126	0.0142	CcSEcCtD
Bicalutamide—Urinary retention—Varenicline—nicotine dependence	0.0121	0.0136	CcSEcCtD
Bicalutamide—Liver function test abnormal—Varenicline—nicotine dependence	0.0117	0.0132	CcSEcCtD
Bicalutamide—Dry skin—Varenicline—nicotine dependence	0.0116	0.0131	CcSEcCtD
Bicalutamide—Breast disorder—Varenicline—nicotine dependence	0.0115	0.0129	CcSEcCtD
Bicalutamide—Gastritis—Varenicline—nicotine dependence	0.0112	0.0126	CcSEcCtD
Bicalutamide—CYP2C19—CYP2E1 reactions—CYP2A7—nicotine dependence	0.011	0.0991	CbGpPWpGaD
Bicalutamide—Dysphagia—Varenicline—nicotine dependence	0.011	0.0123	CcSEcCtD
Bicalutamide—Asthma—Varenicline—nicotine dependence	0.011	0.0123	CcSEcCtD
Bicalutamide—Angina pectoris—Varenicline—nicotine dependence	0.0107	0.012	CcSEcCtD
Bicalutamide—Bronchitis—Varenicline—nicotine dependence	0.0105	0.0119	CcSEcCtD
Bicalutamide—CYP2D6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0102	0.0912	CbGpPWpGaD
Bicalutamide—Pollakiuria—Varenicline—nicotine dependence	0.0101	0.0114	CcSEcCtD
Bicalutamide—Erectile dysfunction—Varenicline—nicotine dependence	0.0101	0.0114	CcSEcCtD
Bicalutamide—CYP2C9—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0101	0.0904	CbGpPWpGaD
Bicalutamide—Weight increased—Varenicline—nicotine dependence	0.00998	0.0112	CcSEcCtD
Bicalutamide—Hyperglycaemia—Varenicline—nicotine dependence	0.00989	0.0111	CcSEcCtD
Bicalutamide—Depression—Varenicline—nicotine dependence	0.00975	0.011	CcSEcCtD
Bicalutamide—Acute coronary syndrome—Varenicline—nicotine dependence	0.00964	0.0108	CcSEcCtD
Bicalutamide—Myocardial infarction—Varenicline—nicotine dependence	0.00958	0.0108	CcSEcCtD
Bicalutamide—Conjunctivitis—Varenicline—nicotine dependence	0.0095	0.0107	CcSEcCtD
Bicalutamide—Hepatobiliary disease—Varenicline—nicotine dependence	0.00925	0.0104	CcSEcCtD
Bicalutamide—Epistaxis—Varenicline—nicotine dependence	0.00922	0.0104	CcSEcCtD
Bicalutamide—Sinusitis—Varenicline—nicotine dependence	0.00917	0.0103	CcSEcCtD
Bicalutamide—Bradycardia—Varenicline—nicotine dependence	0.00894	0.0101	CcSEcCtD
Bicalutamide—Urinary tract disorder—Varenicline—nicotine dependence	0.00867	0.00975	CcSEcCtD
Bicalutamide—Oedema peripheral—Varenicline—nicotine dependence	0.00865	0.00973	CcSEcCtD
Bicalutamide—Urethral disorder—Varenicline—nicotine dependence	0.0086	0.00968	CcSEcCtD
Bicalutamide—Visual impairment—Varenicline—nicotine dependence	0.00846	0.00952	CcSEcCtD
Bicalutamide—Cardiac disorder—Varenicline—nicotine dependence	0.00815	0.00917	CcSEcCtD
Bicalutamide—Angiopathy—Varenicline—nicotine dependence	0.00796	0.00896	CcSEcCtD
Bicalutamide—Immune system disorder—Varenicline—nicotine dependence	0.00793	0.00892	CcSEcCtD
Bicalutamide—CYP2D6—Fatty acids—CYP2A7—nicotine dependence	0.00792	0.0711	CbGpPWpGaD
Bicalutamide—Mediastinal disorder—Varenicline—nicotine dependence	0.00791	0.0089	CcSEcCtD
Bicalutamide—Chills—Varenicline—nicotine dependence	0.00788	0.00886	CcSEcCtD
Bicalutamide—Arrhythmia—Varenicline—nicotine dependence	0.00784	0.00882	CcSEcCtD
Bicalutamide—Mental disorder—Varenicline—nicotine dependence	0.00769	0.00865	CcSEcCtD
Bicalutamide—Malnutrition—Varenicline—nicotine dependence	0.00764	0.0086	CcSEcCtD
Bicalutamide—Flatulence—Varenicline—nicotine dependence	0.00753	0.00847	CcSEcCtD
Bicalutamide—Back pain—Varenicline—nicotine dependence	0.00739	0.00832	CcSEcCtD
Bicalutamide—Muscle spasms—Varenicline—nicotine dependence	0.00735	0.00827	CcSEcCtD
Bicalutamide—Anaemia—Varenicline—nicotine dependence	0.00706	0.00795	CcSEcCtD
Bicalutamide—Angioedema—Varenicline—nicotine dependence	0.00698	0.00786	CcSEcCtD
Bicalutamide—Syncope—Varenicline—nicotine dependence	0.00685	0.00771	CcSEcCtD
Bicalutamide—CYP2C19—Xenobiotics—CYP2A7—nicotine dependence	0.00684	0.0614	CbGpPWpGaD
Bicalutamide—Loss of consciousness—Varenicline—nicotine dependence	0.00672	0.00756	CcSEcCtD
Bicalutamide—Cough—Varenicline—nicotine dependence	0.00667	0.0075	CcSEcCtD
Bicalutamide—Hypertension—Varenicline—nicotine dependence	0.0066	0.00742	CcSEcCtD
Bicalutamide—Myalgia—Varenicline—nicotine dependence	0.00651	0.00732	CcSEcCtD
Bicalutamide—Chest pain—Varenicline—nicotine dependence	0.00651	0.00732	CcSEcCtD
Bicalutamide—Anxiety—Varenicline—nicotine dependence	0.00648	0.0073	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.00646	0.00727	CcSEcCtD
Bicalutamide—Dry mouth—Varenicline—nicotine dependence	0.00636	0.00716	CcSEcCtD
Bicalutamide—CYP2D6—Xenobiotics—CYP2A7—nicotine dependence	0.00629	0.0565	CbGpPWpGaD
Bicalutamide—CYP2C9—Xenobiotics—CYP2A7—nicotine dependence	0.00624	0.056	CbGpPWpGaD
Bicalutamide—Oedema—Varenicline—nicotine dependence	0.00624	0.00702	CcSEcCtD
Bicalutamide—Infection—Varenicline—nicotine dependence	0.0062	0.00697	CcSEcCtD
Bicalutamide—Shock—Varenicline—nicotine dependence	0.00614	0.0069	CcSEcCtD
Bicalutamide—Nervous system disorder—Varenicline—nicotine dependence	0.00612	0.00688	CcSEcCtD
Bicalutamide—Thrombocytopenia—Varenicline—nicotine dependence	0.00611	0.00687	CcSEcCtD
Bicalutamide—Skin disorder—Varenicline—nicotine dependence	0.00606	0.00682	CcSEcCtD
Bicalutamide—Hyperhidrosis—Varenicline—nicotine dependence	0.00603	0.00678	CcSEcCtD
Bicalutamide—Anorexia—Varenicline—nicotine dependence	0.00594	0.00669	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.00568	0.00639	CcSEcCtD
Bicalutamide—Insomnia—Varenicline—nicotine dependence	0.00564	0.00635	CcSEcCtD
Bicalutamide—Dyspnoea—Varenicline—nicotine dependence	0.00556	0.00626	CcSEcCtD
Bicalutamide—Somnolence—Varenicline—nicotine dependence	0.00554	0.00624	CcSEcCtD
Bicalutamide—Dyspepsia—Varenicline—nicotine dependence	0.00549	0.00618	CcSEcCtD
Bicalutamide—Decreased appetite—Varenicline—nicotine dependence	0.00542	0.0061	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00538	0.00606	CcSEcCtD
Bicalutamide—Fatigue—Varenicline—nicotine dependence	0.00538	0.00605	CcSEcCtD
Bicalutamide—Pain—Varenicline—nicotine dependence	0.00533	0.006	CcSEcCtD
Bicalutamide—Constipation—Varenicline—nicotine dependence	0.00533	0.006	CcSEcCtD
Bicalutamide—Feeling abnormal—Varenicline—nicotine dependence	0.00514	0.00578	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Varenicline—nicotine dependence	0.0051	0.00574	CcSEcCtD
Bicalutamide—Urticaria—Varenicline—nicotine dependence	0.00495	0.00557	CcSEcCtD
Bicalutamide—Abdominal pain—Varenicline—nicotine dependence	0.00493	0.00555	CcSEcCtD
Bicalutamide—Body temperature increased—Varenicline—nicotine dependence	0.00493	0.00555	CcSEcCtD
Bicalutamide—Hypersensitivity—Varenicline—nicotine dependence	0.00459	0.00517	CcSEcCtD
Bicalutamide—Asthenia—Varenicline—nicotine dependence	0.00447	0.00503	CcSEcCtD
Bicalutamide—Pruritus—Varenicline—nicotine dependence	0.00441	0.00496	CcSEcCtD
Bicalutamide—Diarrhoea—Varenicline—nicotine dependence	0.00427	0.0048	CcSEcCtD
Bicalutamide—Dizziness—Varenicline—nicotine dependence	0.00412	0.00464	CcSEcCtD
Bicalutamide—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.00411	0.0369	CbGpPWpGaD
Bicalutamide—Vomiting—Varenicline—nicotine dependence	0.00397	0.00446	CcSEcCtD
Bicalutamide—Rash—Varenicline—nicotine dependence	0.00393	0.00442	CcSEcCtD
Bicalutamide—Dermatitis—Varenicline—nicotine dependence	0.00393	0.00442	CcSEcCtD
Bicalutamide—Headache—Varenicline—nicotine dependence	0.00391	0.0044	CcSEcCtD
Bicalutamide—Nausea—Varenicline—nicotine dependence	0.0037	0.00417	CcSEcCtD
Bicalutamide—AR—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00304	0.0273	CbGpPWpGaD
Bicalutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00284	0.0255	CbGpPWpGaD
Bicalutamide—CYP2C19—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.0028	0.0252	CbGpPWpGaD
Bicalutamide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00261	0.0235	CbGpPWpGaD
Bicalutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00259	0.0233	CbGpPWpGaD
Bicalutamide—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00258	0.0232	CbGpPWpGaD
Bicalutamide—CYP2C9—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00256	0.023	CbGpPWpGaD
Bicalutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.0023	0.0207	CbGpPWpGaD
Bicalutamide—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00212	0.019	CbGpPWpGaD
Bicalutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.0021	0.0189	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00203	0.0182	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00184	0.0165	CbGpPWpGaD
Bicalutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00171	0.0153	CbGpPWpGaD
Bicalutamide—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00169	0.0151	CbGpPWpGaD
Bicalutamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00138	0.0124	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—AKR1B10—nicotine dependence	0.0013	0.0117	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—CYP2A7—nicotine dependence	0.00122	0.011	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00121	0.0108	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00119	0.0107	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00118	0.0106	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.00113	0.0101	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—CYP2A7—nicotine dependence	0.00112	0.01	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00111	0.00997	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—CYP2A7—nicotine dependence	0.0011	0.00988	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—CCAR1—nicotine dependence	0.001	0.00898	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00078	0.00701	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000736	0.00661	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000725	0.00652	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP2A7—nicotine dependence	0.000209	0.00188	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP2A7—nicotine dependence	0.000192	0.00173	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP2A7—nicotine dependence	0.000191	0.00171	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP2A7—nicotine dependence	0.000126	0.00113	CbGpPWpGaD
